Perspectives therapeutiques de l'insuffisance cardiaque.

Nellessen, E.; Pierard, Luc

Download

Article (Scientific journals)

Perspectives therapeutiques de l'insuffisance cardiaque.

Nellessen, E.; Pierard, Luc

2012 • In Revue Médicale Suisse, 8 (351), p. 1591-7

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/170803

PubMed
22988712

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

RMS_351_1591.pdf

Publisher postprint (670.44 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular Agents/therapeutic use; Cardiovascular Surgical Procedures; Defibrillators, Implantable; Heart Failure/therapy; Humans

Abstract :

[en] Heart failure constitutes a major public health problem. Its incidence continues to grow and its prognosis remains poor. Therapeutic approach of chronic heart failure with left ventricular systolic dysfunction is well codified. Recommended medical treatment is presented with the description of the different therapeutic classes. Recent advances are discussed. New therapeutic targets are described. Optimization of recognized treatment and application to heart failure of drugs used for other indications are developed. Therapeutic approach of heart failure with preserved ejection fraction is tackled but stays far less well defined. Many studies concerning treatment of acute heart failure are ongoing.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Nellessen, E.

Pierard, Luc ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

French

Title :

Perspectives therapeutiques de l'insuffisance cardiaque.

Alternative titles :

[en] Perspectives in the management of congestive heart failure

Publication date :

2012

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

351

Pages :

1591-7

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 July 2014

Statistics

Number of views

447 (10 by ULiège)

Number of downloads

580 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

** Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008;10:933-89.
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More «malignant» than cancer ? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-22. (Pubitemid 32895839)
* Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-46. (Pubitemid 47311002)
Stromberg A. The crucial role of patient education in heart failure. Eur J Heart Fail 2005;7:363-9. (Pubitemid 40253569)
** Dickstein K, Vardas PE, Auricchio A, et al. Focused update of ESC guidelines on device therapy in heart failure : An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronisation therapy. Eur Heart J 2010;31:2677-87.
** Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet 2011;378:722-30.
Batista JR, Verde J, Nery P, et al. Partial left ventriculectomy to treat end-stage heart disease. Ann Thorac Surg 1997;6:634-8. (Pubitemid 27435668)
** Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-eight adult heart transplant report - 2011. J Heart Lung Transplant 2011;30:1078-94.
Boilson BA, Raichlin E, Park SJ, et al. Device therapy and cardiac transplantation for end-stage heart failure. Curr Probl Cardio 2010;35:8-64.
** McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure : Putting guidelines into practice. Eur J Heart Fail 2005;17:710-21. (Pubitemid 41125884)
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. (Pubitemid 32479962)
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors : The CHARM-alternative trial. Lancet 2003;362:772-6. (Pubitemid 37093917)
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. (RALES Study). N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
Anker SD, Coats AJ. How to RECOVER from RENAISSANCE ? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30. (Pubitemid 35284800)
Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure ? Int J Cardiol 2002;85:195-7. (Pubitemid 35245980)
Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure : The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6. (Pubitemid 34925324)
Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure : Outcome study with zolvaptan (EVEREST). J Card Fail 2005;11:260-9. (Pubitemid 40626781)
Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.
Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL Study) : A randomised double-blind trial. Lancet 2009;374:1840-8.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : Results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet 2000;355:253-9.
Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8. (Pubitemid 37093919)
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
* Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure : Results from Val-HeFT. Circulation 2005;23;112:1121-7. (Pubitemid 41216118)
Tanner H, Moschovitis G, Kuster GM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002;86:115-21.
Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure : A substudy of the Elite II trial. Eur Heart J 2004;25:1021-8. (Pubitemid 38869420)
* Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75. (Pubitemid 41785934)
Flannery G, Gehrig-Mills J, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-9.
* Komajda M, Follath F, Swedberg K, et al. The EuroHeart failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2 : Treatment. Eur Heart J 2003;24:464-74. (Pubitemid 36286188)
Borer JS, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina : A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-23.
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT) : A randomised placebo-controlled study. Lancet 2010;376:875-85.
McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14.
Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial : A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011;162:966-72.
Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2009;2:320-4.
Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine : Outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304-11.
Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes : Results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent : A randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J 2009;157:1035-41.
Massie BM, O'Connor M, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28.
O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.